<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568398</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-438/OCT-304</org_study_id>
    <secondary_id>U1111-1128-6012</secondary_id>
    <secondary_id>JapicCTI-121790</secondary_id>
    <nct_id>NCT01568398</nct_id>
  </id_info>
  <brief_title>A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the safety and efficacy of TAK-438, once daily (QD), in&#xD;
      participants with a history of gastric or duodenal ulcer requiring long-term low-dose aspirin&#xD;
      therapy will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Gastric Ulcer</condition>
  <condition>Duodenal Ulcer</condition>
  <arm_group>
    <arm_group_label>TAK-438 20 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-438</intervention_name>
    <arm_group_label>TAK-438 20 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants who, in the opinion of the principal investigator or subinvestigator, are&#xD;
             capable of understanding the details of the study and complying with them.&#xD;
&#xD;
          2. Prior to study commencement, participants who are capable of signing and dating the&#xD;
             information/consent form.&#xD;
&#xD;
          3. Participants with a chronic disease (ischaemic cardiac disease, ischaemic&#xD;
             cerebrovascular disease, etc.) which requires continuous low-dose aspirin oral therapy&#xD;
             for prevention of thromboembolism during the treatment period.&#xD;
&#xD;
          4. Participants who meet either 1 or 2 below according to gastric or duodenal endoscopy:&#xD;
&#xD;
               -  Ulcer scar (defined, in this study, as regenerative mucosa, convergence of&#xD;
                  mucosal fold, gastric wall transformation, etc) has been confirmed during&#xD;
                  endoscopy on the study drug initiation day (Visit 2).&#xD;
&#xD;
               -  Ulcer (mucosal defects of 3 mm or larger with white moss) or ulcer scar has been&#xD;
                  endoscopically confirmed before the study drug initiation day (Visit 2).&#xD;
&#xD;
          5. Outpatient participants (inpatients for examinations are acceptable).&#xD;
&#xD;
          6. Women with child-bearing potential must agree to routinely take appropriate&#xD;
             contraceptive measures throughout treatment period, from giving consent to the study&#xD;
             until 4 weeks after the final dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants who received treatment with another study drug (including approved drugs&#xD;
             under post-marketing surveillance) within 84 days prior to commencement of screening&#xD;
&#xD;
          2. Participants who have previously received TAK-438 in a clinical study or as a&#xD;
             treatment&#xD;
&#xD;
          3. Participants who are employees of institutions participating in this study and family&#xD;
             members of such employees, participants in a dependent relationship with employees of&#xD;
             institutions involved in conduct of the study (e.g., spouse, parent, child, sibling),&#xD;
             and participants who are under duress in giving their consent&#xD;
&#xD;
          4. Participant who have donated 400 mL or more of blood within 90 days prior to the&#xD;
             commencement of screening&#xD;
&#xD;
          5. Participants with a plan to change the type, dosage or administration of low-dose&#xD;
             aspirin.&#xD;
&#xD;
          6. Participants with ulcer (mucosal defects of 3 mm or larger with white moss) or active&#xD;
             hemorrhage confirmed during gastric or duodenal endoscopy on the study drug initiation&#xD;
             day (Visit 2)&#xD;
&#xD;
          7. Participants with small intestinal hemorrhage, large intestinal hemorrhage, or&#xD;
             gastrointestinal hemorrhage of unknown cause&#xD;
&#xD;
          8. Participants with a history of surgery or scheduled surgery influencing gastric acid&#xD;
             secretion (resection of upper gastrointestinal tract or vagotomy etc)&#xD;
&#xD;
          9. Participants with a history or complication of Zollinger-Ellison syndrome, or other&#xD;
             gastric acid hypersecretion disorders&#xD;
&#xD;
         10. Participants with a history or complication of aspirin asthma&#xD;
&#xD;
         11. Participants who have a history of hypersensitivity or allergy to TAK-438 (including&#xD;
             its excipients) or aspirin or salicylic acid agents.&#xD;
&#xD;
         12. Participants with current use of illicit drug or a history of drug abuse. and/or&#xD;
             alcohol dependence within one year prior to the commencement of screening&#xD;
&#xD;
         13. Participants who require treatment with prohibited concomitant drugs or therapies (see&#xD;
             7.3)&#xD;
&#xD;
         14. Female participants who are pregnant or lactating; those who plan to become pregnant&#xD;
             or donate ova during treatment period, from giving consent until 4 weeks after final&#xD;
             dose&#xD;
&#xD;
         15. Participants with serious central nervous system disorders, cardiovascular disease,&#xD;
             pulmonary disease, hepatic disease, renal disease, metabolic disease, gastrointestinal&#xD;
             disorders, urinary disorders, endocrine disease, or blood dyscrasia&#xD;
&#xD;
         16. Participants who plan to undergo surgery requiring hospitalization or requires surgery&#xD;
             during the study period&#xD;
&#xD;
         17. Participants with a history of a malignancy (or treatment thereof) within 5 years&#xD;
             prior to the commencement of screening; however, participants with completely cured of&#xD;
             basal cell carcinoma of skin or carcinoma in situ of the cervix may be included in the&#xD;
             study.&#xD;
&#xD;
         18. Participants with acquired immune deficiency syndrome (AIDS; including HIV carriers)&#xD;
             or hepatitis (including viral hepatitis carriers [HBs antigen positive or HCV antibody&#xD;
             positive]); however, Participants who are hepatitis C virus (HCV) antigen negative or&#xD;
             HCV-RNA negative may be included in the study.&#xD;
&#xD;
         19. Participants who meet either of the following laboratory test values at the beginning&#xD;
             of screening (Visit 1)&#xD;
&#xD;
               -  Serum creatinine value: higher than 2 mg/dL&#xD;
&#xD;
               -  Alanine transaminase (ALT) or aspartate aminotransferase (AST): higher than 2.5 ×&#xD;
                  the upper limit of normal&#xD;
&#xD;
               -  Total bilirubin: higher than 2.0 × the upper limit of normal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Funabashi-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Noda-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annaka-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hakodate-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitahiroshima-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yubari-gun</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa-shi</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sanuki-shi</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sasebo-shi</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuchu-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katsushika-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nakano-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric or duodenal ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Ulcer</mesh_term>
    <mesh_term>Duodenal Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

